SG11201408530YA - Method for producing monomeric and multimeric molecules and uses thereof - Google Patents

Method for producing monomeric and multimeric molecules and uses thereof

Info

Publication number
SG11201408530YA
SG11201408530YA SG11201408530YA SG11201408530YA SG11201408530YA SG 11201408530Y A SG11201408530Y A SG 11201408530YA SG 11201408530Y A SG11201408530Y A SG 11201408530YA SG 11201408530Y A SG11201408530Y A SG 11201408530YA SG 11201408530Y A SG11201408530Y A SG 11201408530YA
Authority
SG
Singapore
Prior art keywords
multimeric molecules
producing monomeric
monomeric
producing
multimeric
Prior art date
Application number
SG11201408530YA
Other languages
English (en)
Inventor
Johannes Auer
Martin Bader
Stefan Dengl
Stefan Lorenz
Stefan Seeber
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11201408530YA publication Critical patent/SG11201408530YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
SG11201408530YA 2012-08-02 2013-07-31 Method for producing monomeric and multimeric molecules and uses thereof SG11201408530YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12179021 2012-08-02
PCT/EP2013/066096 WO2014020069A1 (en) 2012-08-02 2013-07-31 Method for producing monomeric and multimeric molecules and uses thereof

Publications (1)

Publication Number Publication Date
SG11201408530YA true SG11201408530YA (en) 2015-03-30

Family

ID=48914281

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408530YA SG11201408530YA (en) 2012-08-02 2013-07-31 Method for producing monomeric and multimeric molecules and uses thereof

Country Status (13)

Country Link
US (3) US20150218250A1 (es)
EP (1) EP2880169B1 (es)
JP (1) JP6388581B2 (es)
KR (1) KR20150037959A (es)
CN (1) CN104508133B (es)
BR (1) BR112015002091A2 (es)
CA (1) CA2876099A1 (es)
ES (1) ES2633894T3 (es)
HK (1) HK1208880A1 (es)
MX (1) MX2015000683A (es)
RU (1) RU2015106812A (es)
SG (1) SG11201408530YA (es)
WO (1) WO2014020069A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201606597QA (en) 2014-03-05 2016-09-29 Ucb Biopharma Sprl Multimeric fc proteins
BR112017000689A2 (pt) 2014-07-15 2018-01-23 Astellas Pharma Inc. novo anticorpo tie-2 anti-humano
WO2016071377A1 (en) 2014-11-06 2016-05-12 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and protein a-binding properties
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN109071613A (zh) 2016-05-11 2018-12-21 通用电气医疗集团生物工艺研发股份公司 分离基质
WO2017194593A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
US11708390B2 (en) 2016-05-11 2023-07-25 Cytiva Bioprocess R&D Ab Method of storing a separation matrix
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
WO2018025809A1 (ja) * 2016-08-01 2018-02-08 株式会社カネカ カルシプロテインパーティクルの吸着材、および吸着除去システムとその利用方法
KR102050463B1 (ko) 2016-08-10 2019-11-29 아주대학교산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물
US20190352363A1 (en) * 2016-12-22 2019-11-21 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3688036A4 (en) 2017-09-25 2021-06-23 Dingfu Biotarget Co., Ltd PROTEINOUS HETERODIMER AND USE OF IT
KR20210005169A (ko) 2018-04-25 2021-01-13 프로메테우스 바이오사이언시즈, 인크. 최적화된 항tl1a 항체
AU2019366956A1 (en) 2018-10-23 2021-05-20 Dragonfly Therapeutics, Inc. Heterodimeric Fc-fused proteins
MX2022004942A (es) 2019-10-24 2022-07-27 Prometheus Biosciences Inc Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos.
US11952411B2 (en) 2020-08-19 2024-04-09 Janssen Biotech, Inc. Materials and methods of using engineered ligands

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4105480A1 (de) * 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
US6284236B1 (en) * 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
BR9908226A (pt) 1998-02-25 2000-10-24 Lexigen Pharm Corp Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo
CA2338000C (en) 1998-07-17 2009-12-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Water-soluble 4-thio-maleimido derivatives and methods for their production
CN1341121A (zh) * 1999-01-07 2002-03-20 利思进药品公司 作为Fc融和蛋白之抗肥胖蛋白质的表达和外运
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP4944324B2 (ja) * 1999-07-13 2012-05-30 ボルダー バイオテクノロジー， インコーポレイテッド 免疫グロブリン融合タンパク質
JP5179689B2 (ja) * 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
HUP0303246A2 (hu) 2001-02-23 2003-12-29 Immunex Corporation Aktív fehérjék fokozott kinyerése
US7736657B2 (en) * 2002-02-10 2010-06-15 Apoxis S.A. Fusion constructs containing active sections on TNF ligands
EP2027151A2 (en) 2006-05-15 2009-02-25 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
AT505262A1 (de) 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid
WO2010048313A2 (en) 2008-10-22 2010-04-29 Biogen Idec Ma Inc. Recombinant fcrn and variants thereof for purification of fc-containing fusion proteins
EP2184070A1 (en) 2008-11-07 2010-05-12 Hla-G Technologies HLA-G proteins and pharmaceutical uses thereof
ES2692268T3 (es) * 2011-03-29 2018-12-03 Roche Glycart Ag Variantes de Fc de anticuerpo
WO2012146630A1 (en) * 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof

Also Published As

Publication number Publication date
CA2876099A1 (en) 2014-02-06
US11254728B2 (en) 2022-02-22
JP2015531591A (ja) 2015-11-05
US20170342128A1 (en) 2017-11-30
US20150218250A1 (en) 2015-08-06
JP6388581B2 (ja) 2018-09-12
EP2880169B1 (en) 2017-05-17
CN104508133A (zh) 2015-04-08
WO2014020069A1 (en) 2014-02-06
RU2015106812A (ru) 2016-09-27
HK1208880A1 (en) 2016-03-18
US10570188B2 (en) 2020-02-25
US20200157183A1 (en) 2020-05-21
BR112015002091A2 (pt) 2017-12-12
MX2015000683A (es) 2015-04-10
KR20150037959A (ko) 2015-04-08
CN104508133B (zh) 2018-04-20
EP2880169A1 (en) 2015-06-10
ES2633894T3 (es) 2017-09-25

Similar Documents

Publication Publication Date Title
HK1208880A1 (en) Method for producing monomeric and multimeric molecules and uses thereof
IL281148A (en) New and used KIF5B-RET fusion compounds
HK1214831A1 (zh) 新型融合分子及其應用
HK1206041A1 (en) Methods and means for the production of ig-like molecules
HK1210189A1 (en) Method for the production and selection of molecules comprising at least two different entities and uses thereof
ZA201406671B (en) Multispecific antigen-binding molecules and uses thereof
EP2931319A4 (en) MODIFIED NUCLEIC ACID MOLECULES AND THEIR USES
IL234234B (en) 2ang binding molecules
EP2814865A4 (en) PROCESS FOR PRODUCING POLYMER AND POLYMER PRODUCT
EP2918694A4 (en) STEEL ELEMENT AND PROCESS FOR PRODUCING THE SAME
EP2871482A4 (en) MICROCHIP AND METHOD FOR PRODUCING THE SAME
ZA201503542B (en) Novel immunotherapeutic molecules and uses thereof
ZA201405063B (en) Sealed-edge mirror and method for production thereof
EP2925777A4 (en) MONOLITH-BASED PSEUDO BIOAFFINITY CLEANING PROCEDURES FOR FACTOR VIII AND APPLICATIONS THEREOF
GB201213778D0 (en) Process and dressng
GB201218715D0 (en) Novel method and products
GB201208146D0 (en) Method and product